Cargando…

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity

SIMPLE SUMMARY: The era of immune checkpoint blockade (ICB) with nivolumab and pembrolizumab (anti-PD-1) alone or in combination with ipilimumab (anti-CTLA-4) has led to prolonged survival in patients with cutaneous melanoma (CM). However, the response to ICB is low in patients with uveal melanoma (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koch, Elias A. T., Petzold, Anne, Wessely, Anja, Dippel, Edgar, Gesierich, Anja, Gutzmer, Ralf, Hassel, Jessica C., Haferkamp, Sebastian, Kähler, Katharina C., Knorr, Harald, Kreuzberg, Nicole, Leiter, Ulrike, Loquai, Carmen, Meier, Friedegund, Meissner, Markus, Mohr, Peter, Pföhler, Claudia, Rahimi, Farnaz, Schadendorf, Dirk, Schell, Beatrice, Schlaak, Max, Terheyden, Patrick, Thoms, Kai-Martin, Schuler-Thurner, Beatrice, Ugurel, Selma, Ulrich, Jens, Utikal, Jochen, Weichenthal, Michael, Ziller, Fabian, Berking, Carola, Heppt, Markus V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833453/ https://www.ncbi.nlm.nih.gov/pubmed/35158786 http://dx.doi.org/10.3390/cancers14030518

Ejemplares similares

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
por: Koch, Elias A. T., et al.
Publicado: (2021)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

Clinical determinants of long-term survival in metastatic uveal melanoma
por: Koch, Elias A. T., et al.
Publicado: (2021)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
por: Knispel, Sarah, et al.
Publicado: (2020)

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
por: Tietze, Julia K., et al.
Publicado: (2018)

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
por: Haist, Maximilian, et al.
Publicado: (2023)

Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
por: Stege, Henner, et al.
Publicado: (2021)

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
por: Haist, Maximilian, et al.
Publicado: (2022)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance
por: Wessely, Anja, et al.
Publicado: (2021)

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
por: Ugurel, Selma, et al.
Publicado: (2017)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
por: Berking, Carola, et al.
Publicado: (2023)

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry
por: Moritz, Rose K.C., et al.
Publicado: (2021)

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
por: Amaral, Teresa, et al.
Publicado: (2020)

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
por: Wessely, Anja, et al.
Publicado: (2020)

Spontaneous regression rates of actinic keratosis: a systematic review and pooled analysis of randomized controlled trials
por: Steeb, Theresa, et al.
Publicado: (2022)

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
por: Placke, Jan-Malte, et al.
Publicado: (2023)

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)
por: Steeb, Theresa, et al.
Publicado: (2020)

Conventional and three-dimensional photography as a tool to map distribution patterns of in-transit melanoma metastases on the lower extremity
por: Müller, Kilian, et al.
Publicado: (2023)

Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives
por: Heppt, Markus V., et al.
Publicado: (2022)

Increasing Participation Rates in Germany’s Skin Cancer Screening Program (HELIOS): Protocol for a Mixed Methods Study
por: Steeb, Theresa, et al.
Publicado: (2021)

Opportunities to inform German residents about the possibility of skin cancer screening and to inform stakeholders to take appropriate actions: A qualitative approach
por: Steeb, Theresa, et al.
Publicado: (2023)

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
por: Franklin, Cindy, et al.
Publicado: (2023)

How to Assess the Efficacy of Interventions for Actinic Keratosis? A Review with a Focus on Long-Term Results
por: Steeb, Theresa, et al.
Publicado: (2021)

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS
por: KAATZ, Martin, et al.
Publicado: (2022)

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients
por: Lodde, Georg, et al.
Publicado: (2021)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
por: Glutsch, Valerie, et al.
Publicado: (2022)

The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments
por: Steeb, Theresa, et al.
Publicado: (2020)

Experiences of In-Patients with Skin Cancer in a German University Hospital Setting: A Cross-Sectional Survey
por: Steeb, Theresa, et al.
Publicado: (2021)

eImmunonkologie: Development and Launch of a Virtual Education Platform for the Immunotherapy of Cutaneous Neoplasms
por: Kaufmann, Matthias D., et al.
Publicado: (2022)

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
por: Becker, Jürgen C., et al.
Publicado: (2017)

Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma
por: Wendlinger, Simone, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials
por: Steeb, Theresa, et al.
Publicado: (2020)

The Value of Total Body Photography for the Early Detection of Melanoma: A Systematic Review
por: Hornung, Annkathrin, et al.
Publicado: (2021)

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
por: Hecht, Markus, et al.
Publicado: (2018)

A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis
por: Wessely, Anja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a3lsdqbjgjb16opa2pp7bnrrhi